SCHEMBL613309

SCHEMBL613309

CCNc1cc(Br)sc1C(N)=O

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IKBKB O14920 10/20 0.40
GSK3B P49841 1/20 0.39
MKNK1 Q9BUB5 1/20 0.38
MKNK2 Q9HBH9 1/20 0.38
SIRT2 Q8IXJ6 1/20 0.38
ALDH1A1 P00352 3/20 0.37
KDM4E B2RXH2 2/20 0.37
MAPT P10636 2/20 0.37
HPGD P15428 2/20 0.37
GAA P10253 1/20 0.37
THRB P10828 1/20 0.37
HTT P42858 1/20 0.37
GFER P55789 1/20 0.37
PLEC Q15149 1/20 0.37
MEN1 O00255 2/20 0.37
KMT2A Q03164 2/20 0.37
HSD17B10 Q99714 1/20 0.37
STAT3 P40763 1/20 0.35
LMNA P02545 1/20 0.32
POLB P06746 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL614197 0.82 IKBKB (0.41) IKBKBGSK3BALDH1A1KDM4EKMT2A
SCHEMBL613592 0.82 KDM4E (0.40) GSK3BALDH1A1KDM4EMAPTHPGD
SCHEMBL612154 0.81 IKBKB (0.53) IKBKBGSK3BALDH1A1KDM4EGAA
SCHEMBL614698 0.80 GSK3B (0.36) IKBKBGSK3BMKNK2
SCHEMBL490588 0.77 IKBKB (0.57) IKBKBGSK3BMEN1KMT2A
SCHEMBL20572261 0.76 IKBKB (0.47) IKBKBGSK3BKDM4EMAPTSMN1; SMN2
SCHEMBL611765 0.75 CDC7 (0.50) GSK3BMKNK2ALDH1A1KDM4EMAPT
SCHEMBL16246374 0.72 GSK3B (0.42) IKBKBGSK3BALDH1A1MAPTGAA
SCHEMBL21712645 0.72 IKBKB (0.43) IKBKBALDH1A1KDM4EMAPTHPGD
SCHEMBL612303 0.72 MAPT (0.51) ALDH1A1KDM4EMAPTHPGDGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2403857-B1 THIENOPYRIMIDINE AS CDC7 KINASE INHIBITORS TAKEDA PHARMACEUTICAL (JP) 2013-12-04 EP disclosed
US-20120040981-A1 THIENOPYRIMIDINE AS CDC7 KINASE INHIBITORS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-02-16 US disclosed
EP-2403857-A1 THIENOPYRIMIDINE AS CDC7 KINASE INHIBITORS Takeda Pharmaceutical Company Limited (JP) 2012-01-11 EP disclosed
WO-2010101302-A1 THIENOPYRIMIDINE AS CDC7 KINASE INHIBITORS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-09-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120040981-A1 THIENOPYRIMIDINE AS CDC7 KINASE INHIBITORS CDC7, CDK7, DTYMK IKBKB 993/4885GSK3B 656/4885MKNK1 282/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.